Table 1.
Patient characteristics
| Category | Patients N = 41 |
|---|---|
| Age, years, median (range) | 57.0 (21–80) |
| Females, n (%) | 16 (39) |
| ≥1 past and/or current medical condition at baseline (%) | 31 (76) |
| ECOG PS, n (%) | |
| 0 | 16 (39) |
| 1 | 25 (61) |
| Solid tumor, n (%) | 21 (51.2) |
| Tumor type | |
| Prostate | 5 (12.2) |
| Head and neck | 2 (4.9) |
| Ovarian | 2 (4.9) |
| Pancreas | 2 (4.9) |
| Soft tissue sarcoma | 2 (4.9) |
| Endometrial/uterine, mesothelioma, gastric, colona | 4 (9.8) |
| Other | 4 (9.8) |
| Stage, n (%) | |
| III | 2 (4.9) |
| IV | 19 (89.5) |
| Lymphoma (NHL), n (%) | 20 (48.7) |
| DLBCL | 15 (75) |
| GCBb | 14 (53)d |
| Follicular | 4(20) |
| Transformedc | 3 (75) |
| MZL | 1 (5) |
| Ann Arbor stage, n (%) | |
| IA | 1 (2.4) |
| IIA | 2 (4.9) |
| IIIA | 5 (12.2) |
| IVA | 11 (26.8) |
| IVB | 1 (2.4) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; PS, performance status.
a
One of each tumor type.
b
Percentage calculated as a proportion of all DLBCL.
c
Calculated as a percentage of all FL.
d
Eight confirmed centrally by immunohistochemistry; six could not be confirmed centrally due to limited availability of sample or inconclusive results.